ixazomib + melphalan + prednisone

This is a **three-drug oral combination regimen** consisting of ixazomib, melphalan, and prednisone, developed for the treatment of **newly diagnosed multiple myeloma** in patients who are not eligible for stem cell transplantation. **Ixazomib** is an orally administered proteasome inhibitor, **melphalan** is an alkylating agent, and **prednisone** is a corticosteroid. - **Mechanism of action:** Ixazomib selectively inhibits the 20S proteasome, disrupting proteostasis and leading to cell death in malignant plasma cells. Melphalan induces DNA crosslinking, causing cytotoxicity mainly in dividing tumor cells. Prednisone exerts anti-inflammatory and direct cytotoxic effects on lymphoid tissue. - **Developer and clinical context:** Investigated primarily for its convenience and efficacy as an all-oral regimen, especially for elderly or transplant-ineligible multiple myeloma patients, it aims to offer an alternative to regimens containing parenteral proteasome inhibitors[1][2]. - **Primary indication:** newly diagnosed, transplant-ineligible multiple myeloma[1][2][3].

Other names

ixazomib-melphalan-prednisoneIMP